Targeting O-GlcNAcylation in tumor-associated inflammation: From molecular mechanisms to cancer therapy

Abstract

O-GlcNAcylation is a reversible protein post-translational modification. Imbalance in the O-GlcNAcylation cycle plays a crucial role in the occurrence and development of cancer, the therapeutic potential of targeting O-GlcNAcylation in tumor remains underexplored. The inflammatory response is also closely related to the occurrence and development of tumors. Targeting inflammation-related pathways or combining them with other therapies has emerged as a pivotal strategy in cancer intervention. Future research must delve into the spatiotemporal dynamics of tumor-specific inflammatory networks to advance the development of precision therapeutic strategies, a pressing challenge that remains to be addressed in clinical practice.Therefore, exploring the mechanism of action between O-GlcNAcylation and inflammatory response is extremely important for developing new targeted therapies for cancer. The role of inflammation progression regulated by O-GlcNAcylation in the treatment of tumors is summarized, providing a theoretical basis for the development of new targeted therapies in clinical practice.